

Company Registration Number: 10399052

REGISTRAR'S COPY
PLEASE SIGN AND RETURN

Myogenes Limited

Filleted Unaudited Financial Statements

For the period ended 30th September 2017

FRIDAY



A739RDGH

A23

06/04/2018

#245

COMPANIES HOUSE

Myogenes Limited

Financial Statements

period from 28th September 2016 to 30th September 2017

Contents	Page
Officers and professional advisers	1
Statement of financial position	2
Statement of changes in equity	3
Notes to the financial statements	4

Myogenes Limited
Officers and Professional Advisers

The board of directors

M.H. Brenner
Mrs C. Coverman

Registered office

201 Great Portland Street,
London,
W1W 5AB

Accountants

Benjamin, Taylor & Co.,
Chartered accountants
201, Great Portland Street,
London,
W1W 5AB

Myogenes Limited
Statement of Financial Position
30th September 2017

	Note	£	30 Sep 17 £
Current Assets			
Debtors	5	12,043	
Cash at bank and in hand		<u>17,776</u>	
		29,819	
Creditors: amounts falling due within one year	6	<u>82,636</u>	
Net Current Liabilities			<u>52,817</u>
Total Assets Less Current Liabilities			<u>(52,817)</u>
Net Liabilities			<u>(52,817)</u>
Capital and Reserves			
Called up share capital			1,000
Profit and loss account	7		<u>(53,817)</u>
Members Deficit			<u>(52,817)</u>

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.


For the period ending 30th September 2017 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the period in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements were approved by the board of directors and authorised for issue on 20th March 2018, and are signed on behalf of the board by:

M.H. Brenner
Director



Mrs C. Coverman
Director



Company registration number: 10399052

The notes on pages 4 to 6 form part of these financial statements.

Myogenes Limited

Statement of Changes in Equity

period from 28th September 2016 to 30th September 2017

	Called up share capital £	Profit and loss account £	Total £
At 28th September 2016	–	–	–
Loss for the period	–	(53,817)	(53,817)
Total Comprehensive Income for the Period	–	(53,817)	(53,817)
Issue of shares	1,000	–	1,000
Total Investments by and Distributions to Owners	1,000	–	1,000
At 30th September 2017	<u>1,000</u>	<u>(53,817)</u>	<u>(52,817)</u>

The notes on pages 4 to 6 form part of these financial statements.

Myogenes Limited

Notes to the Financial Statements

period from 28th September 2016 to 30th September 2017

1. General Information

The Company is a private company limited by shares, incorporated in England and Wales. The registered office address is 201, Great Portland Street, London, W1W 5AB.

The principal business activity of the company is that of genetic testing.

2. Statement of Compliance

These financial statements have been prepared in compliance with the provisions of FRS 102 Section 1A, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.

3. Accounting Policies

Basis of Preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Going Concern

After making enquiries the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. For this reason they continue to adopt the going concern basis in preparing the financial statements.

Revenue Recognition

The turnover shown in the profit and loss account represents amounts invoiced during the period, for genetic tests, exclusive of Value Added Tax.

4. Employee Numbers

The average number of persons employed by the company during the period, including the directors, amounted to 3.

5. Debtors

	30 Sep 17
	£
Trade debtors	9,179
Other debtors	2,864
	<u>12,043</u>

Myogenes Limited

Notes to the Financial Statements (continued)

period from 28th September 2016 to 30th September 2017

6. Creditors: amounts falling due within one year

	30 Sep 17
	£
Trade creditors	10,599
Social security and other taxes	538
Other creditors	<u>71,499</u>
	<u><u>82,636</u></u>

7. Reserves

Profit and loss account

The profit and loss account reserve records retained earnings and accumulated losses.

	30 Sep 17
Loss for the financial period	(53,817)
losses carried forward	<u>(53,817)</u>

Share Capital

Called-up share capital represents the nominal value of shares that have been issued.

8. Related Party Transactions

During the year the company had the following transactions with the directors / shareholders:

M.H. Brenner

	30 Sep 17
	£
Monies advanced to Myogenes Limited	(35,000)
Monies repaid to M.H. Brenner	<u>193</u>
Balance carried forward	<u>(34,807)</u>

Z. Zahavi

	30 Sep 17
	£
Monies advanced to Myogenes Limited	(35,279)
Balance carried forward	<u>(35,279)</u>

The above loans are interest free, unsecured and with no fixed date for repayment.

Myogenes Limited

Notes to the Financial Statements *(continued)*

period from 28th September 2016 to 30th September 2017

9. Ultimate Controlling Party

The company was under the joint control of M.H. Brenner and Z. Zahavi from 28th September 2016 to 28th September 2017 by virtue of their 100% ownership of the issued share capital of the company.

From the 28th September 2017 the company has been under the joint control of Mrs C. Coverman, M.H. Brenner and E. Marom by virtue of their 100% ownership of the issued share capital of the company.